Combined systemic and mucosal immunization with microsphere-encapsulated inactivated simian immunodeficiency virus elicits serum, vaginal, and tracheal antibody responses in female rhesus macaques

AIDS Research and Human Retroviruses

Volumn 15, Issue 12, 1999, Pages 1121-1136

  Israel, Zimra R ^a,f   Gettie, Agegnehu ^b   Ishizaka, Sally T ^a   Mishkin, Eric M ^a   Staas, Jay ^c   Gilley, Richard ^c   Montefiori, David ^d   Marx, Preston A ^b,e   Eldridge, John H ^a  

^a PFIZER INC   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

^c SOUTHERN RESEARCH INSTITUTE   (United States)

^d DUKE UNIVERSITY   (United States)

^e TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

^f Wyeth   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 140; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INACTIVATED VACCINE; MICROSPHERE; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; FEMALE; IMMUNOSTIMULATION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRATRACHEAL DRUG ADMINISTRATION; MUCOSAL IMMUNITY; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; TREATMENT OUTCOME; VACCINATION; VACCINIA VIRUS; VIRUS INFECTION;

ANIMALS; ANTIBODIES, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNITY, MUCOSAL; MACACA MULATTA; MICROSPHERES; NEUTRALIZATION TESTS; SIMIAN IMMUNODEFICIENCY VIRUS; TRACHEA; VAGINA; VIRAL VACCINES;

EID: 0033543121     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922299310412     Document Type: Article

References (39)

1. Millman G and Sharma O: Mechanisms of HIV/SFV mucosal transmission. AIDS Res Hum Retroviruses 1994;10:1305.
2. Chin J: Global estimates of AIDS cases and HIV infection. AIDS 1991;5(Suppl. 2):S57.
3. Warren JT and Levinson MA: Preclinical AIDS vaccine development: Formal survey of global HIV, SIV, and SHIV in vivo challenge studies in vaccinated nonhuman primates. J Med Primatol 1997;26(1-2):63-81.
4. Israel ZR, Edmonson PF, Maul DH, O'Neil SP, Mossman SP, Thiriart C, Fabry L, Van Opstal O, Bruck C, Bex F, Burny A, Fultz P, Mullins J, and Hoover E: Incomplete protection, but suppression of virus burden, elicited by subunit simian immunodeficiency virus vaccines. J Virol 1994;68(3):1843-1853.
5. Daniel MD, Mazzara GP, Simon MA, Sehgal PK, Kodama T, Panicali DL, and Desrosiers RC: High-titer immune responses elicited by recombinant vaccinia virus priming and particle boosting are ineffective in preventing virulent SIV infection. AIDS Res Hum Retroviruses. 1994;10(7):839-851.
6. Heeney JL, Holterman L, ten Haaft P, Dubbes R, Koornstra W, Teeuwsen V, Bourquin P, Norley S, and Niphuis H: Vaccine protection and reduced virus load from heterologous macaque-propagated SIV challenge. AIDS Res Hum Retroviruses 1994;10(Suppl. 2):S117-S121.
7. Stahl-Hennig C, Dittmer U, Nisslein T, Petry H, Jurkiewicz E, Fuchs D, Wachter H, Matz-Rensing K, Kuhn EM, Kaup FJ, Rud EW, and Hunsmann G: Rapid development of vaccine protection in macaques by live-attenuated simian immunodeficiency virus. J Gen Virol 1996;77:2969-2981.
8. Crange M, Baskerville A, Ashworth L, Dennis M, Cook N, Sharpe S, Farrar G, Rose J, Kitchin P, and Greenway P: Intrarectal challenge of macaques vaccinated with formalin-inactivated simian immunodeficiency virus. Lancet 1992;339:273-274.
9. Buge S, Richardson E, Alipanah S, Markham P, Cheng S, Kalyan N, Miller C, Lubeck M, Udem S, Eldridge J, and Robert-Guroff M: An adenovirus simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge. J Virol 1997;71:8531-8541.
10. Moore A, McGuirk P, Adams S, Jones W, McGhee J, O'Hagan D, and Mills K: Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells. Vaccine 1995;13:1741-1749.
11. O'Hagan D, McGhee J, Holmgren J, Mowat A, Donachie A, Mills K, Gaisford W, Rahman D, and Challacombe S: Biodegradable microparticles for oral immunization. Vaccine 1993;11:149-154.
12. Marx P, Compans R, Gettie A, Staas J, Gilley R, Mulligan M, Yamshchikov G, Chen D, and Eldridge J: Protection against vaginal SIV transmission with microencapsulated vaccine. Science 1993;260:1323-1327.
13. O'Hagan D, Palin K, Davis S, Arthurson P, and Sjoholm I: Microparticles as potentially orally active immunological adjuvants. Vaccines 1992;9:47-52.
14. Eldridge J, Staas J, Meulbroek J, McGhee J, Tice T, and Gilley R: Biodegradable microspheres as a vaccine delivery system. Mol Immunol 1991;28:287-294.
15. Goldstein S, Elkins W, London W, Hahn A, Goeken R, Martin J, and Hirsch V: Immunization with whole inactivated vaccine protects from infection by SIV grown in human but not macaque cells. J Med Primatol 1994;23(2-3):75-82.
16. Stott EJ: Anti-cell antibody in macaques. Nature (London) 1991; 353(6343):393.
17. LeGrand R, Vogt G, Vaslin B, Roques P, Theodora F, Aubertin A, and Dormont D: Specific and non-specific immunity and protection of macaques against SIV infection. Vaccine 1992;10:873-879.
18. Hu S-L, Abrams K, Barber G, Moran P, Zarling J, Langlois A, Kuller L, Morton W, and Benveniste R: Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science 1992;255:456-459.
19. Israel Z and Marx P: Nonclassical mucosal antibodies predominate in genital secretions of HIV-1 infected chimpanzees: J Med Primatol 1995;24:53-60.
20. Miller C, Kwang C, Marthas M, Moldovenau Z, Kiyono H, Marx P, Eldridge J, Mestecky J, and McGhee J: Genital secretory immune response to chronic simian immunodeficiency virus (SIV) infection: A comparison between intravenously and genitically inoculated rhesus macaques. Clin Exp Immunol 1992;88:520-526.
21. Miller C, Alexander N, Sujipto S, Lackner A, Gettie A, Hendrickx A, Lowenstine L, Jennings M, and Marx P: Genital mucosal transmission of simian immunodeficiency virus: animal model for heterosexual transmission of human immunodeficiency virus. J Virol 1989;63:4277-4284.
22. Montefiori D, Baba T, Li A, Bilska M, and Ruprecht R: Neutralizing and infection-enhancing antibody responses do not correlate with the differential pathogenicity of SIVmac239 delta 3 in adult and infant rhesus monkeys. J Immunol 1996;157:5528-5535.
23. Chen Z, Telfer P, Gettie A, Reed P, Zhang L, Ho D, and Marx P: Genetic characterization of new West African simian immunodeficiency virus SIVsm: Geographic clustering of household-derived SIV strains with human immunodeficiency virus type 2 subtypes and genetically diverse viruses from a single feral sooty mangabey troop. J Virol 1996;70:3617-3627.
24. Ogra P and Ogra S: Local antibody response to polio vaccine in the human female genital tract. J Immunol 1973;110:1307-1311.
25. Belec L, Georges A, Steinman G, and Martin P: Antibodies to human immunodeficiency virus in vaginal secretions of heterosexual women. J Infect Dis 1989;160:385-389.
26. Lu X, Belec L, and Pillot J: Anti gp160 IgG and IgA antibodies associated with a large increase in total IgG in cervicovaginal secretions from human immunodeficiency virus type-1 infected women. J Infect Dis 1993;167:1189-1192.
27. A. Ishizaka S, Israel Z, Gettie A, Mishkin E, Eldridge J, and Marx P: Induction of mucosal antibody reponses by microsphere-encapsulated formalin-inactivated SIV in a male urethral challenge model. Vaccine 1999; in press.
28. Bouvet J, Belec L, and Pilot J: Immunoglobulin G antibodies in human vaginal secretions after parenteral vacination. Infect Immun 1994;62:3957-3961.
29. Wolff M, Mayer K, Seape G, Politch J, Horsburger C, and Anderson D: A comparison of HIV-1 classes, titers, and specificities in paired semen and blood samples from HIV-1 infected persons. AIDS 1992;5:65-69.
30. Lohman B, McChesney M, Miller C, Otsyula M, Berardi C, and Marthas M: Mucosal immunization with a live, virulence-attenuated simian immunodeficiency virus (SIV) vaccine elicits antiviral cytotoxic T lymphocytes and antibodies in rhesus macaques. J Med Primatol 1994;23(2-3):95-101.
31. Kubota M, Miller C, Imaoka K, Kawabata S, Fujihashi K, McGhee J, and Kiyono H: Oral immunization with simian immunodeficiency virus p55gag and cholera toxin elicits both mucosal IgA and systemic IgG immune responses in nonhuman primates. J Immunol 1997;158(11):5321-5329.
32. Thapar M, Parr E, and Parr M: Sercretory immune responses in mouse vaginal fluid after pelvic, parenteral or vaginal immunization. Immunology 1990;70:121-125.
33. Herman P, Gregory T, Lavon R, Nakamura G, Champe M, Porter J, Wurm F, Hershberg R, Cobb E, and Eichberg J: Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature (London) 1990;345:622-625.
34. Eimini E, Nara P, Schleif W, Lewis J, Lee D, Kessler J, Conley A, Matsushita S, Putney S, Gerety R, and Eichberg J: Antibody-mediated in vitro neutralization of human immunodeficiency virus type 1 abolishes infectivity for chimpanzees. J Virol 1990;64:3674-3678.
35. Hulskotte E, Geretti A, Siebelink K, van Amerongen G, Cranage M, Rud E, Norley S, de Vries P, and Osterhaus A: Vaccine-induced virus-neutralizing antibodies and cytotoxic T cells do not protect macaques from experimental infection with simian immunodeficiency virus SIVmac32H (J5). J Virol 1995;69(10): 6289-6296.
36. Clements J, Montelaro R, Zink M, Martin-Amedee A, Miller S, Trichel A, Jagersi B, Hauer D, Martin L, Bohm R, and Murphey-Corb M: Cross-protective immune responses induced in rhesus macaques by immunization with attenuated macrophage-tropic simian immunodeficiency virus. J Virol 1995;69:2737-2744.
37. Langolis A, Desrosiers R, Lewis M, Kewalramani V, Littman D, Zhou J, Manson K, Wyand M, Bolognesi D, and Montefiori D: Neutralizing antibodies in sera from macaques immunized with attenuated simian immunodeficiency virus. J Virol 1998;72: 6950-6955.
38. Dean M, Carrington M, Winkler C, Hutfley G, Smith, Alikmets R, Goedert J, Buchbinder S, Vittinghoff E, Gomperts E, Donfield S, Vlahov E, Kaslow R, Saah A, Rinaldo C, Detels . Multicenter AIDS Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study, and O'Brien S: Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 1996;273:1856-1862.
39. Chen Z, Zhou P, Ho D, Landau N, and Marx P: Genetically divergent strains of simian immunodeficiency virus use CCR5 as co-receptor for entry. J Virol 1997;71:2705-2714.